Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 1998

View Archived Issues

Company Profile: AdProTech

Phytera and Galileo enter into collaborative agreement

Rhone-Poulenc Rorer expands licensing agreement with Enzon for Oncaspar

CombiChem achieves milestone in Roche Bioscience collaboration

Maxim's mucosal vaccine research published

The Liposome Company: Q1 1998 highlights

Oxygent research agreement restructured

SciClone and Schering-Plough begin phase III trial of Zadaxin in Japan

Neurocrine Biosciences: Q1 1998 highlights

Merck characterizes new orally bioavailable thrombin inhibitor: L-374087

Ondansetron suppresses spontaneous sleep apnea in rats

Muse approved in Sweden

Barr receives FDA approval for generic form of ReVia

Rhone-Poulenc Rorer submits NDA for ebastine in U.S.

Oncogene Science Diagnostics and Fujirebio form cancer diagnostics collaboration

Another market introduction for Xalatan

SU-5416 advances to phase I/II trials in Kaposi's sarcoma

MRI with alpha(v)/beta(3)-targeted MAb as a method of detecting tumor angiogenesis

Recombinant antithrombin III pivotal clinical trials begin

AtheroGenics receives FDA approval to begin AGI-1067 trial

Unimed discontinues U.S. registration process for nitazoxanide indication

FDA advisory committee recommends approval of Thyrogen

European Commission approves Novartis' Exelon

U.S. patent issues for ImClone Systems' flk-1/KDR receptor-targeting antibodies

Scios and Janssen to copromote Risperdal

Palatin finalizes license for erectile dysfunction product

Mechanism of antitumor activity of clotrimazole identified

Zonagen, Schering AG to drop contraceptive vaccine collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...